Movatterモバイル変換


[0]ホーム

URL:


Skip to main content
medRxiv

Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada

David N.Fisman,View ORCID ProfileAshleigh R.Tuite
doi: https://doi.org/10.1101/2021.07.05.21260050
David N. Fisman
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,Canada
MD MPH
Ashleigh R. Tuite
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,Canada
PhD MPH
Loading

Abstract

Background The period from February to June 2021 was one during which initial wild-type SARS-CoV-2 strains were supplanted in Ontario, Canada, first by variants of concern (VOC) with the N501Y mutation (Alpha/B1.1.17, Beta/B.1.351 and Gamma/P.1 variants), and then by the Delta/B.1.617 variant. The increased transmissibility of these VOCs has been documented but data for increased virulence is limited. We used Ontario’s COVID-19 case data to evaluate the virulence of these VOCs compared to non-VOC SARS-CoV-2 infections, as measured by risk of hospitalization, intensive care unit (ICU) admission, and death.

Methods We created a retrospective cohort of people in Ontario testing positive for SARS-CoV-2 and screened for VOCs, with dates of test report between February 7 and June 22, 2021 (n=211,197). We constructed mixed effects logistic regression models with hospitalization, ICU admission, and death as outcome variables. Models were adjusted for age, sex, time, comorbidities, and pregnancy status. Health units were included as random intercepts.

Results Compared to non-VOC SARS-CoV-2 strains, the adjusted elevation in risk associated with N501Y-positive variants was 59% (49-69%) for hospitalization; 105% (82-134%) for ICU admission; and 61% (40-87%) for death. Increases with Delta variant were more pronounced: 120% (93-153%) for hospitalization; 287% (198-399%) for ICU admission; and 137% (50-230%) for death.

Interpretation The progressive increase in transmissibility and virulence of SARS-CoV-2 VOCs will result in a significantly larger, and more deadly, pandemic than would have occurred in the absence of VOC emergence.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Work approved by the Research Ethics Board of the University of Toronto

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding statement: The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

  • Declaration of competing interests: Dr. Fisman has served on advisory boards related to influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, Astrazeneca and Sanofi-Pasteur Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario.

  • Updated to correct error (pregnancy numbers) in Table 1. Analysis repeated using multilevel model with bootstrapped confidence interval rather than parameteric CI. MS reformatted for Canadian Medical Assoc. Journal.

Data Availability

Data are not currently publicly available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
Posted July 12, 2021.
Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada
David N.Fisman,Ashleigh R.Tuite
medRxiv2021.07.05.21260050;doi: https://doi.org/10.1101/2021.07.05.21260050
Twitter logoFacebook logoLinkedIn logoMendeley logo
Subject Areas

[8]ページ先頭

©2009-2025 Movatter.jp